Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9768074 | 0.79 | ADRB2 (0.63) | KDM4EADRB2BCHEADRB3ADRB1 | |
| SCHEMBL10879276 | 0.76 | KDM4E (0.64) | KDM4EADRB2BCHEADRB3 | |
| SCHEMBL10877567 | 0.75 | KDM4E (0.88) | KDM4EBCHE | |
| SCHEMBL19330018 | 0.75 | KDM4E (0.63) | KDM4EADRB2BCHEADRB3ADRB1 | |
| SCHEMBL10877574 | 0.75 | KDM4E (0.88) | KDM4EBCHE | |
| SCHEMBL10332396 | 0.75 | KDM4E (0.52) | KDM4EADRB2BCHEADRB3ADRB1 | |
| SCHEMBL4868791 | 0.75 | ADRB2 (0.87) | KDM4EADRB2ADRB1 | |
| Norbudrine SCHEMBL2732733 | 0.75 | ADRB2 (0.65) | KDM4EADRB2ADRB3ADRB1 | |
| Norbudrine SCHEMBL29387737 | 0.75 | ADRB2 (0.65) | KDM4EADRB2ADRB3ADRB1 | |
| SCHEMBL11810755 | 0.74 | KDM4E (0.51) | KDM4EADRB2BCHEADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5462965-A | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | GD SEARLE & CO. (US) | 1995-10-31 | — | — | US | disclosed |